ADBIOTECH Co.,Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name ADBIOTECH Co.,Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 257.5%
- Equity ratio
- 28.0%
- ROE
- -24.6%
- Op. margin
- -27.1%
- Rev. growth
- 15.8%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 310.5% | 24.4% | -52.2% | -13.1% | n/a |
| FY2022 consolidated | 91.6% | 52.2% | 16.7% | -46.4% | -10.2% |
| FY2023 consolidated | 159.0% | 38.6% | -50.1% | -45.5% | -1.5% |
| FY2024 consolidated | 675.6% | 12.9% | -302.1% | -37.0% | 6.3% |
| FY2025 consolidated | 257.5% | 28.0% | -24.6% | -27.1% | 15.8% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩11.8B | ₩10.6B | ₩10.5B | ₩11.1B | ₩12.9B |
| Operating profit | -₩1.6B | -₩4.9B | -₩4.8B | -₩4.1B | -₩3.5B |
| Pre-tax income | -₩2.4B | ₩2.7B | -₩5.5B | -₩9.0B | -₩3.5B |
| Net income | -₩2.7B | ₩2.7B | -₩5.4B | -₩9.0B | -₩3.3B |
| Total assets | ₩21.0B | ₩31.0B | ₩28.1B | ₩23.1B | ₩48.4B |
| Total liabilities | ₩15.9B | ₩14.8B | ₩17.2B | ₩20.1B | ₩34.9B |
| Total equity | ₩5.1B | ₩16.2B | ₩10.8B | ₩3.0B | ₩13.5B |
| Paid-in capital | ₩3.8B | ₩4.6B | ₩4.6B | ₩4.6B | ₩8.2B |
| Debt/equity (source value) | 310.5% | 91.6% | 159.0% | 675.6% | 257.5% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2000-06-16
- Listed
- 22/01/24
- Employees
- 64
- Auditor
- n/a
- Audit opinion
- n/a
- Corporate reg. no.
- 1101111999444
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 애드바이오텍Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.